U.S. markets closed

Axsome Therapeutics, Inc. (AXSM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
52.60-0.95 (-1.77%)
At close: 4:00PM EDT

52.60 0.00 (0.00%)
After hours: 7:35PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close53.55
Open53.69
Bid52.39 x 800
Ask54.54 x 1100
Day's Range52.11 - 54.74
52 Week Range51.00 - 109.53
Volume198,060
Avg. Volume305,978
Market Cap1.968B
Beta (5Y Monthly)2.54
PE Ratio (TTM)N/A
EPS (TTM)-2.77
Earnings DateMay 06, 2021 - May 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est143.85
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why Is Axsome (AXSM) Down 19.9% Since Last Earnings Report?
    Zacks

    Why Is Axsome (AXSM) Down 19.9% Since Last Earnings Report?

    Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Read This Before Selling Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares
    Simply Wall St.

    Read This Before Selling Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • Motley Fool

    1 Green Flag for Axsome Therapeutics

    Axsome Therapeutics (NASDAQ: AXSM) is approaching that important day in the life of a biotech when it shifts from unprofitable company to one that is marketing pharmaceuticals to the public. This specialist in drugs for the central nervous system is applying for two new drug applications with the Food and Drug Administration in 2021, and has two additional drugs just a year or two away from market. In this video clip from Motley Fool Live, recorded March 5, Corinne Cardina, bureau chief of healthcare and cannabis at Fool.com, and Motley Fool contributor Taylor Carmichael discuss Axsome.